Loading organizations...
Loading organizations...
Developing selective PI3K inhibitors for cancer and inflammatory diseases.
Pathway Therapeutics has raised $12.0M across 2 funding rounds.
Pathway Therapeutics has raised $12.0M in total across 2 funding rounds.
Pathway Therapeutics has raised $12.0M in total across 2 funding rounds.
Pathway Therapeutics's investors include CM Capital, GBS Venture Partners, Breast Cancer Research Trust, New Zealand Growth Capital Partners, Trans Tasman Commercialisation Fund.
Pathway Therapeutics has raised $12.0M across 2 funding rounds. Most recently, it raised $7.5M Other Equity in May 2011.
| Date | Round | Lead Investors | Other Investors |
|---|---|---|---|
| May 25, 2011 | $7.5M Other Equity | CM Capital, GBS Venture Partners | |
| Aug 10, 2010 | $4.5M Series A Extension | CM Capital, GBS Venture Partners | Breast Cancer Research Trust, New Zealand Growth Capital Partners, Trans Tasman Commercialisation Fund |